Compare Gartner Inc (IT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs TG Therapeutics Inc — how do they compare? Gartner Inc trades at $180.1 (market cap $11.83B), while TG Therapeutics Inc trades at $49.48 (market cap $7.64B). The key difference: Gartner Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| IT | TGTX | |
|---|---|---|
Market Cap | $11.83B | $7.64B |
Sector | Technology | Health |
52-Week High | $264.09 | $59.06 |
52-Week Low | $125.68 | $26.94 |
Enterprise Value | $13.57B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $180.61, down 6.5% over 24h, yet maintains a bullish technical signal with strong moving average support. The company reported Q2 2026 EPS of $4.37, beating estimates of $3.76 (Zacks Investment Research, 2026-08-07), and raised its full-year EPS and free cash flow guidance. Revenue for 2025 was $6.50B with a net income margin of 12%, though profit margins have softened from 2024 levels. Recent news highlights earnings strength but also a shareholder investigation into fiduciary duties (GlobeNewsWire, 2026-08-12).
The outlook is mixed: strong profitability metrics like a 113.58% ROE and consistent earnings beats support upside potential, but risks include a high P/B ratio of 160.06, ongoing legal scrutiny, and uneven revenue growth. Analyst consensus is cautious with a $172.80 price target below the current price, indicating 55.55% hold ratings amid 27.78% buys.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
